IXA6

Research use only, not for human use.

IXA6, a novel IRE1/XBP1s agonist with potential vasoprotective activity, activates IRE1-XBP1s signaling and XBP1s transcriptional response, making it useful for studying neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.

IXA6 is a novel IRE1/XBP1s activator, and can induce IRE1 RNase activity.

IXA6 (10 μM; 4 or 18 h) selectively activates IRE1-XBP1s signaling, and activates the XBP1s transcriptional response.IXA6 (10 μM; 4 h) shows selectivity for IRE1-XBP1s-dependent ER proteostasis remodeling.IXA6 (10 μM; 18 h) reduces secretion of APP through IRE1 activation.Western Blot AnalysisCell Line:HEK293T cells Concentration:10?μM Incubation Time:18 hoursResult:Increasesd in ER proteostasis factor gene expression correspond to increased protein levels.RT-PCR Cell Line:HEK293T cells Concentration:10?μM Incubation Time:4 hours Result:Activated the IRE1-XBP1s geneset to levels about 30-40% that observed for Tg (Tg representing 100% activation of each gene).Cell Viability Assay Cell Line:HEK293T cells Concentration:10?μM Incubation Time:4 hours Result:Observed high level of overlap (64%) for genes induced by XBP1s and IXA6.RT-PCR Cell Line:Huh7 and SHSY5Y cells Concentration:10?μM Incubation Time:4 hours Result:Upregulated XBP1s mRNA selectively, in cell lines including Huh7 and SHSY5Y cells.RT-PCR Cell Line:CHO cells Concentration:10?μM Incubation Time:18 hours Result:Observed reduction in Aβ secretion blocked by cotreatment with 4μ8c, confirming this reduction is dependent on IRE1 RNAse activity in CHO7WD10 cells stably expressing wild-type APP (APPWT) and in cells treated with the IXA6.

——

——

Others

Other Targets

IRE1

——

——

1021106-40-0

441.93

C22H20ClN3O3S

>98% (HPLC)

In Vitro:?DMSO : 33.33 mg/mL (75.42 mM; Ultrasonic )

ClC1=CC=C(CN(CC(=O)N2CCC3=C2C=CC=C3)S(=O)(=O)C2=CC=CN=C2)C=C1

——

(-20℃)

With Ice Pack

≥ 2 years